scholarly journals Epstein-Barr Virus Reactivation after Infliximab in Rheumatoid Arthritis: A Case Report

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Michele Colaci ◽  
Marco Sebastiani ◽  
Gilda Sandri ◽  
Marisa Meacci ◽  
Clodoveo Ferri
Keyword(s):  
Rheumatoid Arthritis ◽  
Epstein Barr Virus ◽  
Viral Infections ◽  
Therapeutic Strategies ◽  
Tnf Alpha ◽  
Virus Reactivation ◽  
Alpha Blockers ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthritis, but their use has raised the question about their safety profile, particularly in respect to viral infections/reactivations. We describe the case of a patient who developed a symptomatic EBV reactivation 11 days after the first infusion of infliximab.

Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab

2014 ◽  
Vol 59 (4) ◽  
pp. 255-258 ◽  
Author(s):  
Harinder Gill ◽  
Yu-Yan Hwang ◽  
Thomas S.Y. Chan ◽  
Annie W.K. Pang ◽  
Anskar Y.H. Leung ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

OR10 Genetic predisposition to interleukin-10 production influences epstein-barr virus reactivation after renal transplantation

2015 ◽  
Vol 76 ◽  
pp. 21
Author(s):  
Gaurav Tripathi ◽  
Abdulnaser Abadi ◽  
Poonam Dharmani-Khan ◽  
Lee Anne Tibbles ◽  
Serdar Yilmaz ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Genetic Predisposition ◽  
Epstein Barr Virus ◽  
Interleukin 10 ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

scholarly journals Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yun Xie ◽  
Song Cao ◽  
Hui Dong ◽  
Hui Lv ◽  
Xiaolei Teng ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Mortality Rates ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Ebv Reactivation ◽  
Imaging Characteristics ◽  
Single Center Study ◽  
Significant Difference ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation

Abstract Background Our goal is to further elucidate the clinical condition and prognosis of patients with severe acute COVID-19 with EBV reactivation. Method This is a retrospective single-center study of COVID-19 patients admitted to the intensive care unit of Wuhan No. 3 Hospital (January 31 to March 27, 2020). According to whether Epstein-Barr virus reactivation was detected, the patients were divided into an EBV group and a Non-EBV group. Baseline data were collected including epidemiological, larithmics, clinical and imaging characteristics, and laboratory examination data. Results Of the 128 patients with COVID-19, 17 (13.3%) were infected with Epstein-Barr virus reactivation. In the symptoms,the rate of tachypnoea in the EBV group was apparently higher than that in the Non-EBV group. In lab tests, the lymphocyte and albumin of EBV group decreased more significantly than Non-EBV group, and the D-dimer and serum calcium of EBV group was higher than Non-EBV group. Regarding the infection index, CRP of EBV group was apparently above the Non-EBV group, and no significant difference was found in procalcitonin of the two groups. The incidence of respiratory failure, ARDS, and hypoproteinaemia of EBV group had more incidence than Non-EBV group. The 28-day and 14-day mortality rates of EBV group was significantly higher than that of Non-EBV group. Conclusions In the COVID-19 patients, patients with EBV reactivation had higher 28-day and 14-day mortality rates and received more immuno-supportive treatment than patients of Non-EBV group.

Sign in / Sign up

Export Citation Format

Share Document